EGFR and hepatocellular carcinoma: Western blot analysis presented in Figure 5G–K further demonstrates that at a dose of 30 mg/kg, ZAK‐I‐57 significantly (p < 0.05) downregulated EGFR and c‐Myc, two pivotal oncogenic drivers in HCC, indicating strong inhibition of proliferative signaling pathways.